US 11213524
Pharmaceutical compositions for subcutaneous administration of levosimendan
granted A61KA61K31/50A61K47/40
Quick answer
US patent 11213524 (Pharmaceutical compositions for subcutaneous administration of levosimendan) held by TENAX THERAPEUTICS, INC. expires Mon Dec 30 2041 00:00:00 GMT+0000 (Coordinated Universal Time). Status: granted.
Key facts
- Applicant
- TENAX THERAPEUTICS, INC.
- Grant date
- Tue Jan 04 2022 00:00:00 GMT+0000 (Coordinated Universal Time)
- Expiration
- Mon Dec 30 2041 00:00:00 GMT+0000 (Coordinated Universal Time)
- Claims
- 19
- CPC classes
- A61K, A61K31/50, A61K47/40, A61K9/0019, A61K9/19